华润双鹤 (600062.SH) Latest Company News

Sep 1, 2026, 08:56 UTC
China Resources Double Crane announced that its lomustine capsules received a drug registration certificate and were approved for market launch by the National Medical Products Administration on August 25, 2026, with a 6-year data protection period.
Source:
- finance.sina.cn
- aastocks.com
Aug 31, 2026, 08:57 UTC
China Resources Double-Crane Pharmaceutical's controlled subsidiary, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd., received drug registration certificate for its 0.15g oxcarbazepine tablets, approved by the National Medical Products Administration on August 25, 2026, deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Aug 28, 2026, 09:04 UTC
China Resources Double Crane announced a major asset restructuring to acquire a 23.50% stake in Lier Chemical for cash, which would make it the controlling shareholder and change the actual controller to China Resources Co., Ltd.
Source:
- finance.sina.cn
Aug 21, 2026, 09:12 UTC
China Resources Double-Crane Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 946 million yuan, down 3.43% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 09:12 UTC
China Resources Double-Crane Pharmaceutical proposed a cash dividend of 1 yuan per 10 shares (tax included).
Source:
- finance.sina.cn
Aug 18, 2026, 10:09 UTC
China Resources Double Crane received a drug registration certificate from the National Medical Products Administration for lidocaine hydrochloride gel, which is deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Jul 15, 2026, 11:42 UTC
Lier Chemical's controlling shareholder JiuYuan Group and its concert party Huacai Technology plan to transfer a combined 23.50% stake via public solicitation, and have designated China Resources Double-Crane as the first intended transferee.
Source:
Jul 3, 2026, 08:59 UTC
China Resources Shuanghe's subsidiary Shanxi Jinxin Shuanghe Pharmaceutical Co., Ltd. received a drug registration certificate for progesterone soft capsules from the National Medical Products Administration, approving the product for market launch.
Source:
- finance.sina.cn

600062.SH

China Resources Double Crane announced that its lomustine capsules received a drug registration certificate and were approved for market launch by the National Medical Products Administration on August 25, 2026, with a 6-year data protection period.

China Resources Double Crane announced a major asset restructuring to acquire a 23.50% stake in Lier Chemical for cash, which would make it the controlling shareholder and change the actual controller to China Resources Co., Ltd.

China Resources Double-Crane Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 946 million yuan, down 3.43% year-on-year.

China Resources Double-Crane Pharmaceutical proposed a cash dividend of 1 yuan per 10 shares (tax included).

China Resources Double Crane received a drug registration certificate from the National Medical Products Administration for lidocaine hydrochloride gel, which is deemed to have passed consistency evaluation.

Lier Chemical's controlling shareholder JiuYuan Group and its concert party Huacai Technology plan to transfer a combined 23.50% stake via public solicitation, and have designated China Resources Double-Crane as the first intended transferee.

China Resources Shuanghe's subsidiary Shanxi Jinxin Shuanghe Pharmaceutical Co., Ltd. received a drug registration certificate for progesterone soft capsules from the National Medical Products Administration, approving the product for market launch.